Edwards Lifesciences (EW) Tops Q4 EPS by 4c, Offers Guidance

Edwards Lifesciences (NYSE: EW) reported Q4 EPS of $0.59, $0.04 better than the analyst estimate of $0.55. Revenue for the quarter came in at $1.39 billion versus the consensus estimate of $1.36 billion.

GUIDANCE:

Edwards Lifesciences sees Q1 2025 EPS of $0.58-$0.64, versus the consensus of $0.59. Edwards Lifesciences sees Q1 2025 revenue of $1.35-1.43 billion, versus the consensus of $1.36 billion.

For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.

You May Also Be Interested In

• RBC Capital Upgrades Healius Limited (HLS:AU) (PHCRF) to Sector Perform
• Prime Medicine (PRME) Reiterated at Market Outperform by Citizens as PM647 Application Cleared
• SYNNEX Corp. (SNX) Tops Q3 EPS by $1.04, Beats on Revenue; Offers Q4 Guidance